These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19602291)

  • 21. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
    Niskakoski A; Kaur S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Int J Cancer; 2013 Dec; 133(11):2596-608. PubMed ID: 23716351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
    Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG
    BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
    Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
    Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
    Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
    PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 28. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
    Swisher EM; Sakai W; Karlan BY; Wurz K; Urban N; Taniguchi T
    Cancer Res; 2008 Apr; 68(8):2581-6. PubMed ID: 18413725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.
    Kim YM; Lee SW; Chun SM; Kim DY; Kim JH; Kim KR; Kim YT; Nam JH; van Hummelen P; MacConaill LE; Hahn WC; Jang SJ
    PLoS One; 2014; 9(6):e99451. PubMed ID: 24936796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Causes and consequences of microsatellite instability in endometrial carcinoma.
    Gurin CC; Federici MG; Kang L; Boyd J
    Cancer Res; 1999 Jan; 59(2):462-6. PubMed ID: 9927063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
    Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
    Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
    J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    Heemskerk-Gerritsen BAM; Hollestelle A; van Asperen CJ; van den Beek I; van Driel WJ; van Engelen K; Gómez Garcia EB; de Hullu JA; Koudijs MJ; Mourits MJE; Hooning MJ; Boere IA
    PLoS One; 2022; 17(9):e0275015. PubMed ID: 36137114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
    Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
    Dhillon VS; Shahid M; Husain SA
    Mol Cancer; 2004 Dec; 3():33. PubMed ID: 15574200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.